Ki-67 is a prognostic biomarker of survival after radiofrequency ablation of liver malignancies

Annals of Surgical Oncology

Volumn 19, Issue 13, 2012, Pages 4262-4269

  Sofocleous, Constantinos T ^a   Garg, Sandeep ^a   Petrovic, Lydia M ^b   Gonen, Mithat ^a   Petre, Elena N ^a   Klimstra, David S ^a   Solomon, Stephen B ^a   Brown, Karen T ^a   Brody, Lynn A ^a   Covey, Ann M ^a   DeMatteo, Ronald P ^a   Schwartz, Lawrence ^a   Kemeny, Nancy E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b USC UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; CANCER PROGNOSIS; CANCER SURVIVAL; ELECTRODE; FEMALE; FOLLOW UP; HUMAN; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RADIOFREQUENCY ABLATION; REVIEW; TISSUE ADHESION; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CATHETER ABLATION; ELECTRODES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84876493551     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2461-9     Document Type: Review

References (42)

1. Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N. Hepatocellular carcinoma. An overview. Ann Hepatol. 2006;5:16-24.
2. Hildebrand P, Kleemann M, Roblick UJ, et al. Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients. Langenbecks Arch Surg. 2006;391:1-6.
3. Hanna NN. Radiofrequency ablation of primary and metastatic hepatic malignancies. Clin Colorectal Cancer. 2004;4:92-100. (Pubitemid 39199249)
4. Gillams AR. The use of radiofrequency in cancer. Br J Cancer. 2005;92:1825-9. (Pubitemid 40826126)
5. Curley SA, Izzo F. Radiofrequency ablation of primary and metastic liver tumors. Surg Technol Int. 2002;10:99-106.
6. Chen MH, Yang W, Yan K, et al. Treatment efficacy of radiofre-quency ablation of 338 patients with hepatic malignant tumor and the relevant complications. World J Gastroenterol. 2005;11:6395-401. (Pubitemid 43014011)
7. Sofocleous CT, Nascimento RG, Gonen M, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. Am J Roentgenol. 2007;189:883-9. (Pubitemid 47479772)
8. Meloni MF, Andreano A, Laeseke PF, Livraghi T, Sironi S, Lee FT Jr. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation-intermediate and long-term survival rates. Radiology. 2009;253:861-9.
9. Rhim H, Lim HK, Choi D. Current status of radiofrequency ablation of hepatocellular carcinoma. World J Gastrointest Surg. 2010;2:128-36.
10. Jakobs TF, Hoffmann RT, SchraDer A, et al. CT-guided radio-frequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol. 2009;32:38-46.
11. Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg. 2006;141:181-90. (Pubitemid 43276571)
12. Ng KK, Poon RT. Radiofrequency ablation for malignant liver tumor. Surg Oncol. 2005;14:41-52. (Pubitemid 40380622)
13. Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology. 2000;217:119-26. (Pubitemid 33097587)
14. Harrison LE, Koneru B, Bahramipour P, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepa-tocellular carcinoma. J Am Coll Surg. 2003;197:759-64. (Pubitemid 38199577)
15. White RR, Avital I, Sofocleous CT, et al. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gas-trointest Surg. 2007;11:256-63.
16. Livraghi T, Solbiati L, Meloni MF, Gazelle EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441-51. (Pubitemid 36313433)
17. Lencioni R, Crocetti L, Cioni D, Della Pina C, Bartolozzi C. Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. Invest Radiol. 2004;39:689-97. (Pubitemid 39425962)
18. White TJ, Roy-Choudhury SH, Breen DJ, et al. Percutaneous radiofrequency ablation of colorectal hepatic metastases-initial experience. An adjunct technique to systemic chemotherapy for those with inoperable colorectal hepatic metastases. Dig Surg. 2004;21:314-20. (Pubitemid 39370397)
19. Siperstein A, Garland A, Engle K, et al. Laparoscopic radiofre-quency ablation of primary and metastatic liver tumors. Technical considerations. Surg Endosc. 2000;14:400-5. (Pubitemid 30262386)
20. Adam R, Hagopian EJ, Linhares M, et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg. 2002;137: 1332-9.
21. Snoeren N, Jansen MC, Rijken AM, et al. Assessment of viable tumour tissue attached to needle applicators after local ablation of liver tumours. Dig Surg. 2009;26:56-62.
22. Sofocleous CT, Nascimento RG, Petrovic LM, et al. Histopath-ologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. Radiology. 2008;249:364-74.
23. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269-90. (Pubitemid 32250377)
24. Yang J, Ramnath N, Moysich KB, et al. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer. 2006;6:203.
25. Dodd GD 3rd, Frank MS, Aribandi M, Chopra S, Chintapalli KN. Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations. AJR Am J Roentgenol. 2001;177:777-82. (Pubitemid 32881650)
26. Choi H, Loyer EM, DuBrow RA, et al. Radio-frequency ablation of liver tumors: assessment of therapeutic response and complications. Radiographics. 2001;21(Spec. No.):S41-54.
27. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology. 2005 235:728-39. (Pubitemid 40695866)
28. Graur F, Vlad L, Furcea L, Miclaus D, Osian G. Radiofrequency ablation of liver tumors: technique and preliminary results. Chirurgia (Bucur). 2006;101:159-67.
29. Curley SA. Radiofrequency ablation of malignant liver tumors. Ann Surg Oncol. 2003;10:338-47. (Pubitemid 40486929)
30. Rossi S, Buscarini E, Garbagnati F, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol. 1998;170:1015-22. (Pubitemid 28172891)
31. Solbiati L, Goldberg SN, Ierace T, et al. Hepatic metastases: percutaneous radio-frequency ablation with cooled-tip electrodes. Radiology. 1997;205:367-73.
32. Pulvirenti A, Garbagnati F, Regalia E, et al. Experience with radiofrequency ablation of small hepatocellular carcinomas before liver transplantation. Transplant Proc. 2001;33:1516-7. (Pubitemid 32237955)
33. Sofocleous CT, Klein KM, Hubbi B, et al. Histopathologic evaluation of tissue extracted on the radiofrequency probe after ablation of liver tumors: preliminary findings. AJR Am J Roent-genol. 2004;183:209-13. (Pubitemid 38789039)
34. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212-20.
35. Tollefson MK, Thompson RH, Sheinin Y, et al. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal carcinoma and not surrogates for each other. Cancer. 2007;110:783-90. (Pubitemid 47257655)
36. King KL, Hwang JJ, Chau GY, et al. Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 1998;13:273-9.
37. Garrity MM, Burgart LJ, Mahoney MR, et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group study. J Clin Oncol. 2004;22:1572-82. (Pubitemid 41079794)
38. Toquet C, Le Neel JC, Guillou L, et al. Elevated ([ or = 10 %) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: a study of 35 cases. Dig Dis Sci. 2002;47: 2247-53. (Pubitemid 35205300)
39. Vilar E, Salazar R, Pérez-García J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007;14: 221-32. (Pubitemid 47242624)
40. Weber JC, Nakano H, Bachellier P, et al. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg. 2001;182: 81-8. (Pubitemid 32787119)
41. Yu HC, Cheng JS, Lai KH, et al. Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy. World J Gastroenterol. 2005;11: 1439-44.
42. Snoeren N, Huiskens J, Rijken AM, et al. Viable tumor tissue adherent to needle applicators after local ablation: a risk factor for local tumor progression. Ann Surg Oncol. 2011;18:3702-10.